News
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback